TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Baecklund Johan) > TNF inhibitor thera...

Raaschou, PaulineKarolinska Institutet (författare)

TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis : a nationwide cohort study.

Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

2014-08-08
BMJ,2015
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:uu-273690
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-273690URI
https://doi.org/10.1136/annrheumdis-2014-205745DOI
http://kipublications.ki.se/Default.aspx?queryparsed=id:132537529URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

EB ingår i The ARTIS group
OBJECTIVE: To investigate the risk of breast cancer recurrence in rheumatoid arthritis (RA)-patients with tumour necrosis factor inhibitor (TNFi) treatment and a history of breast cancer, taking several breast cancer, comorbidity and RA-related prognostic factors into account.METHODS: 143 female TNFi-treated patients (1999-2010) with RA and a history of breast cancer before start of TNFi were identified through register linkages, and matched 1:1 from a cohort of 1598 comparable biologics-naive individuals. 120 TNFi-treated and 120 matched biologics-naive individuals with a history of equally recent/distant breast cancer met the eligibility criteria and comprised the final study population. The primary outcome was first recurrence of breast cancer. Through register-linkages and chart review, individuals were followed until 2011. HRs for recurrence were calculated using Cox regression.RESULTS: The median time from breast cancer diagnosis until TNFi-treatment/start of follow-up was 9.4 years. Modest differences in breast cancer characteristics and/or treatment among TNFi-treated and biologics-naive individuals were noted at time of breast cancer diagnosis. Median follow-up from TNFi start was 4.9 years (4.6 years among biologics-naive). Among the TNFi-treated, 9 developed a breast cancer recurrence (crude incidence rate 15/1000 person-years) during follow-up, compared with 9 among the matched biologics-naive (16/1000 person-years). The adjusted corresponding HR was 1.1 (95% CI 0.4 to 2.8).CONCLUSIONS: Among patients with RA and a history of breast cancer, those who started TNFi-treatment did not experience more breast cancer recurrences than patients with RA treated otherwise. The generalisability of our findings to women with a very recent or a poor prognosis of breast cancer remains unknown.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

Frisell, ThomasKarolinska Institutet (författare)
Askling, JohanKarolinska Institutet (författare)
Baecklund, Eva,1956-Uppsala universitet,Reumatologi(Swepub:uu)evaba786 (bidragsgivare)
Karolinska InstitutetReumatologi (creator_code:org_t)

Sammanhörande titlar

Ingår i:Annals of the Rheumatic Diseases: BMJ74:12, s. 2137-21430003-49671468-2060

Internetlänk

Hitta via bibliotek

Annals of the Rheumatic Diseases (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Raaschou, Paulin ...; Frisell, Thomas; Askling, Johan; Baecklund, Eva, ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Reumatologi och ...

Artiklar i publikationen: Annals of the Rh ...

Av lärosätet: Uppsala universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se